{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:04:42Z","timestamp":1790690682998,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bneo.2026.100266","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T22:29:39Z","timestamp":1783117779000},"page":"100266","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating response criteria in myelodysplastic\/myeloproliferative neoplasms: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"3","author":[{"given":"Anthony M.","family":"Hunter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1754-1204","authenticated-orcid":false,"given":"Somedeb","family":"Ball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rena","family":"Buckstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Cargo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2664-3541","authenticated-orcid":false,"given":"Melissa","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devendra","family":"Hiwase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2139-6262","authenticated-orcid":false,"given":"Raphael","family":"Itzykson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8980-3202","authenticated-orcid":false,"given":"Sanam","family":"Loghavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1460-1611","authenticated-orcid":false,"given":"Luca","family":"Malcovati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7677-9119","authenticated-orcid":false,"given":"Moshe","family":"Mittelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Padron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6998-662X","authenticated-orcid":false,"given":"Mrinal M.","family":"Patnaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5439-2172","authenticated-orcid":false,"given":"Valeria","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0837-1231","authenticated-orcid":false,"given":"Daniel","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8311-983X","authenticated-orcid":false,"given":"Arjan A.","family":"Van de Loosdrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0715-1402","authenticated-orcid":false,"given":"Daniel H.","family":"Wiseman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0295-1307","authenticated-orcid":false,"given":"Blanca","family":"Xicoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Savona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4719-7192","authenticated-orcid":false,"given":"Douglas","family":"Tremblay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.bneo.2026.100266_bib1","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.bneo.2026.100266_bib2","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bneo.2026.100266_bib3","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.3324\/haematol.2026.289398","article-title":"Azacitidine for MDS and CMML","volume":"111","author":"Martin","year":"2026","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.bneo.2026.100266_bib4","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bneo.2026.100266_bib5","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2014-10-607341","article-title":"An international consortium proposal of uniform response criteria for myelodysplastic\/myeloproliferative neoplasms (MDS\/MPN) in adults","volume":"125","author":"Savona","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bneo.2026.100266_bib6","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.leukres.2013.01.004","article-title":"Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine","volume":"37","author":"Ad\u00e8s","year":"2013","journal-title":"Leuk Res"},{"issue":"7","key":"10.1016\/j.bneo.2026.100266_bib7","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/ajh.24735","article-title":"Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents","volume":"92","author":"Alfonso","year":"2017","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.bneo.2026.100266_bib8","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ajh.24972","article-title":"A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome\/myeloproliferative neoplasms","volume":"93","author":"Assi","year":"2018","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.bneo.2026.100266_bib9","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1002\/cncr.25759","article-title":"Activity of azacitidine in chronic myelomonocytic leukemia","volume":"117","author":"Costa","year":"2011","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.bneo.2026.100266_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.41","article-title":"Validation of response assessment according to international consortium for MDS\/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents","volume":"7","author":"Duchmann","year":"2017","journal-title":"Blood Cancer J"},{"issue":"suppl 3","key":"10.1016\/j.bneo.2026.100266_bib11","first-page":"1261EP","article-title":"Response and survival outcomes with hypomethylating agents in an Argentinean cohort of 113 patients with chronic myelomonocitic leukemia","volume":"6","author":"Gonzalez","year":"2022","journal-title":"HemaSphere"},{"issue":"22","key":"10.1016\/j.bneo.2026.100266_bib12","doi-asserted-by":"crossref","first-page":"6095","DOI":"10.1158\/1078-0432.CCR-21-0935","article-title":"Integrated human and murine clinical study establishes clinical efficacy of ruxolitinib in chronic myelomonocytic leukemia","volume":"27","author":"Hunter","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.bneo.2026.100266_bib13","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1002\/cam4.3774","article-title":"Real-world data of chronic myelomonocytic leukemia: a Chinese single-center retrospective study","volume":"10","author":"Ma","year":"2021","journal-title":"Cancer Med"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100266_bib14","doi-asserted-by":"crossref","first-page":"6750","DOI":"10.1182\/blood-2024-211137","article-title":"Reduction in MPN-total symptom score (TSS) is associated with overall survival (OS) in chronic myelomonocytic leukemia (CMML)","volume":"144","author":"Padron","year":"2024","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.bneo.2026.100266_bib15","article-title":"Long-term experience with hypomethylating agents in patients with chronic myelomonocytic leukemia","volume":"128","author":"Pierola","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bneo.2026.100266_bib16","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.leukres.2014.01.006","article-title":"Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival","volume":"38","author":"Pleyer","year":"2014","journal-title":"Leuk Res"},{"issue":"2","key":"10.1016\/j.bneo.2026.100266_bib17","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/leu.2017.186","article-title":"A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia","volume":"32","author":"Santini","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.bneo.2026.100266_bib18","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/bjh.20203","article-title":"Efficacy and safety of oral decitabine\/cedazuridine in the chronic myelomonocytic leukaemia subpopulations from phase 2 and 3 studies","volume":"207","author":"Savona","year":"2025","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100266_bib19","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood-2025-791","article-title":"Does stringent cytoreduction improve survival in myeloproliferative chronic myelomonocytic leukemia? a correlative study on the dacota trial","volume":"146","author":"Selimoglu-Buet","year":"2025","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100266_bib20","first-page":"489","article-title":"Hypomethylating agents are effective in shrinking splenomegaly in patients with chronic myelomonocytic leukemia (CMML): Mayo clinic experience","volume":"100","author":"Subari","year":"2015","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.bneo.2026.100266_bib21","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41375-024-02466-6","article-title":"Venetoclax in combination with hypomethylating agents in chronic myelomonocytic leukemia: a propensity score matched multicenter cohort study","volume":"39","author":"Tremblay","year":"2025","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.bneo.2026.100266_bib22","first-page":"2216","article-title":"Prognostic implication of early minimal residual disease evaluation in patients with chronic myelomonocytic leukemia","volume":"12","author":"Wang","year":"2022","journal-title":"Am J Cancer Res"},{"issue":"1","key":"10.1016\/j.bneo.2026.100266_bib23","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/ejh.12679","article-title":"Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia","volume":"97","author":"Xicoy","year":"2016","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bneo.2026.100266_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2021.106640","article-title":"Leukocytosis is associated with end organ damage and mortality in chronic myelomonocytic leukemia and can be mitigated by cytoreductive therapy","volume":"109","author":"Hunter","year":"2021","journal-title":"Leuk Res"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000774?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000774?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:16:28Z","timestamp":1790687788000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328026000774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2950328026000774"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100266","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating response criteria in myelodysplastic\/myeloproliferative neoplasms: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100266","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100266"}}